Innova Therapeutics Advances Novel Cancer Treatment With Enci Therapeutics Deal
Innova Therapeutics has completed its purchase of South Carolina-based biotechnology company Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway. SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes, including overall survival, making it an important therapeutic target. As an SFRP2 antagonist, IVT-8086 selectively blocks the non-canonical Wnt/Ca2+ signaling... Read More »
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion
Johnson & Johnson (J&J) announced on November 17 that it entered into an agreement to acquire Halda Therapeutics. The purchase price is $3.05 billion. Founded by Yale scientist, Professor Craig Crews, Halda Therapeutics is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its business lines include... Read More »
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Limited
JSR Life Sciences LLC, a global leader in life sciences materials and services, announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited. The deal will enable Crown Bioscience to operate as a standalone entity under Adicon’s ownership. The transaction, subject to customary closing conditions, is expected to close in 2026. Financial terms were not disclosed. Crown Bioscience is a contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. The company has a comprehensive portfolio of translational oncology services, including its patient-derived xenograft models, tumor... Read More »
GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million
GSK Plc announced on October 29 that it acquired Syndivia’s preclinical antibody-drug conjugate (ADC). Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific ADC. Syndivia is a French biotechnology company focused on the design and development of ADCs. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer. GSK, formerly... Read More »
TransCode Therapeutics Acquires Polynoma
TransCode Therapeutics, Inc. announced on October 8 that it entered into an agreement to acquire Polynoma LLC. Polynoma is a privately held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
